News

Video

EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Author(s):

Terence Friedlander, MD

Terence Friedlander, MD, presents significant data from the EV-302/KEYNOTE-A39 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Related Videos
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
Vikram M. Narayan, MD
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Nikhil Gopal, MD, assistant professor, urology, College of Medicine, Memphis Department of Urology, The University of Tennessee Health Science Center
Jonathan E. Rosenberg, MD
Joaquim Bellmunt, MD, PhD
Arlene O. Siefker-Radtke, MD
Related Content
Michiel Van der Heijden, MD, PhD, medical oncologist and research group leader at Netherlands Cancer Institute
May 29th 2024

Frontline Nivolumab/Chemo Approved in Europe for Unresectable or Metastatic Urothelial Cancer

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Allliance; associate professor, Department of Medicine, Division of Oncology, clinical director, Genitourinary Cancers Program, University of Washington School of Medicine; associate member, Clinical Research Division, Fred Hutchinson Cancer Center
May 23rd 2024

Advances With Erdafitinib Exemplify the Push For Precision Medicine in Urothelial Cancer

Terence Friedlander, MD
April 24th 2023

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

Vikram M. Narayan, MD, Emory University Hospital; director, urological oncology, Grady Memorial Hospital; assistant professor, Department of Urology, Emory University School of Medicine; member, Winship Cancer Institute
May 15th 2024

Nadofaragene Firadenovec Sets the Stage for Gene Therapies in NMIBC

Petros Grivas, MD, PhD, of Seattle Cancer Care Alliance
May 14th 2024

Grivas Spotlights Advances With Immunotherapy-Based Approaches in Urothelial Cancer